{
  "id": "fda_guidance_chunk_0689",
  "title": "Introduction - Part 689",
  "text": "demonstrate that they are appropriate. Contains Nonbinding Recommendations IV. REFERENCES 1. National Cancer Institute Common Toxicity Criteria, April 30, 1999. (http://ctep.cancer.gov/reporting/CTC-3.html) 2. Division of AIDS Table for Grading Severity of Adult Adverse Experiences; August 1992. (http://rcc.tech-res-intl.com/tox_tables.htm) 3. The Brighton Collaboration. Finalized Case Definitions and Guidelines. (http://brightoncollaboration.org/internet/en/index/definition___guidelines.html) 4. HIV Vaccine Trials Network Table for Grading Severity of Adverse Experiences; September 18, 2002. (http://rcc.tech-res-intl.com/tox_tables.htm) 5. Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, December 2004. (http://www3.niaid.nih.gov/research/resources/DAIDSClinRsrch/PDF/Safety/DAIDSAEGradingTable.pdf) 6. Kratz A, Ferraro M, Sluss PM, Lewandrowski KB. Laboratory Reference Values. New England Journal of Medicine. 2004;351:1548-1563. J:\\!GUIDANC\\5541fnlcln1.doc 07/06/05 Guidance for Industry Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) July 2005 Pharmacology and Toxicology Guidance for Industry Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers Additional copies are available from: Office of Training and Communications Division of Drug Information, HFD-240 Center for Drug Evaluation and Research Food and Drug Administration 5600 Fishers Lane Rockville, MD 20857 (Tel) 301-827-4573 http://www.fda.gov/cder/guidance/index.htm U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) July 2005 Pharmacology and Toxicology TABLE OF CONTENTS I. INTRODUCTION.............................................................................................................1 II. BACKGROUND...............................................................................................................2 III. OVERVIEW OF THE ALGORITHM...........................................................................3 IV. STEP 1: NO OBSERVED ADVERSE EFFECT LEVEL DETERMINATION........5 V. STEP 2: HUMAN EQUIVALENT DOSE CALCULATION......................................6 A. Conversion Based on Body Surface Area....................................................................................6 B. Basis for Using mg/kg Conversions..............................................................................................7 C. Other Exceptions to mg/m2 Scaling Between Species.................................................................8 VI. STEP 3: MOST APPROPRIATE SPECIES SELECTION.........................................9 VII. STEP 4: APPLICATION OF SAFETY FACTOR.......................................................9 A. Increasing the Safety Factor.......................................................................................................10 B. Decreasing the Safety Factor......................................................................................................11 VIII. STEP 5: CONSIDERATION OF THE PHARMACOLOGICALLY ACTIVE DOSE................................................................................................................................12 IX. SUMMARY.....................................................................................................................12 REFERENCES............................................................................................................................13 GLOSSARY.................................................................................................................................15 APPENDIX A:.............................................................................................................................16 Analysis of Allometric Exponent on HED Calculations....................................................................16 APPENDIX B:.............................................................................................................................18 Analysis of Body Weight Effects on HED Calculations....................................................................18 APPENDIX C:.............................................................................................................................24 Derivation of the Interspecies Scaling Factor (Wa/Wh)(1-b)................................................................24 APPENDIX D:.............................................................................................................................25 Examples of Calculations for Converting Animal Doses to Human Equivalent Doses..................25 APPENDIX E:.............................................................................................................................27 Selection of Maximum Recommended Starting Dose for Drugs Administered Systemically to Normal Volunteers...............................................................................................................................27 Contains Nonbinding Recommendations Guidance for Industry1 Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers This guidance",
  "source": "FDA_clinical_trial_guidance.txt",
  "section_heading": "Introduction",
  "start_pos": 924672,
  "end_pos": 926208,
  "tokens": 512,
  "tags": [
    "safety",
    "statistical",
    "regulatory"
  ],
  "jurisdiction": "US",
  "document_type": "fda_guidance",
  "guidance_section": "general_guidance",
  "regulatory_weight": "mandatory",
  "created_at": "2025-10-23T02:25:44.731Z"
}